Summary
4.48 -0.06(-1.21%)09/13/2024
Sana Biotechnology Inc (SANA)
Sana Biotechnology Inc (SANA)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.21 | -15.57 | -6.66 | -33.31 | -50.81 | -19.95 | 0.00 | -87.02 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 4.48 | |
| Open | 4.53 | |
| High | 4.54 | |
| Low | 4.14 | |
| Volume | 2,212,335 | |
| Change | -0.06 | |
| Change % | -1.21 | |
| Avg Volume (20 Days) | 893,735 | |
| Volume/Avg Volume (20 Days) Ratio | 2.48 | |
| 52 Week Range | 2.75 - 12.00 | |
| Price vs 52 Week High | -62.71% | |
| Price vs 52 Week Low | 62.73% | |
| Range | -8.90 | |
| Gap Up/Down | -0.05 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,008 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 37.50 | |
| Book Value | 4.5380 | |
| Earnings Per Share | -2.8850 | |
| EPS Estimate Current Quarter | -0.4900 | |
| EPS Estimate Next Quarter | -0.5600 | |
| EPS Estimate Current Year | -1.9400 | |
| EPS Estimate Next Year | -2.1900 | |
| Diluted EPS (TTM) | -2.8850 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | -0.1954 | |
| Return on equity (TTM) | -0.5225 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 4.0151 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 188,832,992 | |
| Shares Float | 81,490,278 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 12.18 | |
| Institutions (%) | 80.89 | |
08/29 16:05 EST - globenewswire.com
Sana Biotechnology to Present at September 2024 Investor Conferences
SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in September. The presentations will feature a business overview and update.
Sana Biotechnology to Present at September 2024 Investor Conferences
SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in September. The presentations will feature a business overview and update.
08/26 16:05 EST - globenewswire.com
Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer.
Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer.
08/02 19:12 EST - geekwire.com
Sana Biotechnology cuts the ribbon at new manufacturing facility near Seattle
Sana Biotechnology celebrated the beginning of a new chapter on its journey to make drugs that treat complicated diseases, cutting the ribbon outside the company's new manufacturing facility in Bothell, Wash.
Sana Biotechnology cuts the ribbon at new manufacturing facility near Seattle
Sana Biotechnology celebrated the beginning of a new chapter on its journey to make drugs that treat complicated diseases, cutting the ribbon outside the company's new manufacturing facility in Bothell, Wash.
05/08 22:55 EST - investorplace.com
SANA Stock Earnings: Sana Biotechnology Meets EPS for Q1 2024
Sana Biotechnology (NASDAQ: SANA ) just reported results for the first quarter of 2024. Sana Biotechnology reported earnings per share of -32 cents.
SANA Stock Earnings: Sana Biotechnology Meets EPS for Q1 2024
Sana Biotechnology (NASDAQ: SANA ) just reported results for the first quarter of 2024. Sana Biotechnology reported earnings per share of -32 cents.
05/06 16:05 EST - globenewswire.com
Sana Biotechnology to Present at May and June 2024 Investor Conferences
SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in May and June. The presentations will feature a business overview and update.
Sana Biotechnology to Present at May and June 2024 Investor Conferences
SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in May and June. The presentations will feature a business overview and update.
05/03 08:26 EST - zacks.com
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
Notable companies to have witnessed solid earnings acceleration as of now are Sana Biotechnology (SANA), LifeMD (LFMD), Evolus (EOLS) and Expro Group Holdings (XPRO).
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
Notable companies to have witnessed solid earnings acceleration as of now are Sana Biotechnology (SANA), LifeMD (LFMD), Evolus (EOLS) and Expro Group Holdings (XPRO).
04/21 21:02 EST - invezz.com
Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX
Biotech stocks are having a relatively strong year as investors focus on the growing M&A in the healthcare space. Johnson & Johnson is acquiring Shockwave Medical while Novo Nordisk is buying Catalent, a CDMO organization.
Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX
Biotech stocks are having a relatively strong year as investors focus on the growing M&A in the healthcare space. Johnson & Johnson is acquiring Shockwave Medical while Novo Nordisk is buying Catalent, a CDMO organization.
02/29 16:05 EST - globenewswire.com
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes
02/28 16:05 EST - globenewswire.com
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the Cowen 44th Annual Health Care Conference at 2:50 p.m. ET on Wednesday, March 6, 2024. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the Cowen 44th Annual Health Care Conference at 2:50 p.m. ET on Wednesday, March 6, 2024. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
02/18 11:20 EST - 24/7 Wall Street
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to Florida to take advantage of the better income tax environment.
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to Florida to take advantage of the better income tax environment.
02/13 16:05 EST - globenewswire.com
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
Transplant of HIP-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate (NHP), enabling the achievement of exogenous insulin independence without immunosuppression for six month study duration
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
Transplant of HIP-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate (NHP), enabling the achievement of exogenous insulin independence without immunosuppression for six month study duration
02/12 16:05 EST - globenewswire.com
Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SEATTLE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has closed its underwritten upsized public offering of 21,772,728 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 4,500,000 additional shares of its common stock, at a price to the public of $5.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 12,727,272 shares of its common stock at a price to the public of $5.4999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants were sold by Sana. The gross proceeds from the offering were approximately $189.75 million before deducting underwriting discounts and commissions and other offering expenses.
Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SEATTLE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has closed its underwritten upsized public offering of 21,772,728 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 4,500,000 additional shares of its common stock, at a price to the public of $5.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 12,727,272 shares of its common stock at a price to the public of $5.4999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants were sold by Sana. The gross proceeds from the offering were approximately $189.75 million before deducting underwriting discounts and commissions and other offering expenses.
02/08 01:22 EST - globenewswire.com
Sana Biotechnology Announces Pricing of Upsized Public Offering
SEATTLE, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has priced its underwritten upsized public offering of 17,272,728 shares of its common stock at a price to the public of $5.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 12,727,272 shares of common stock at a price to the public of $5.4999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants are to be sold by Sana. In addition, Sana has granted the underwriters a 30-day option to purchase up to an additional 4,500,000 shares of its common stock. The gross proceeds from the offering are expected to be approximately $165.0 million before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about February 12, 2024, subject to satisfaction of customary closing conditions.
Sana Biotechnology Announces Pricing of Upsized Public Offering
SEATTLE, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has priced its underwritten upsized public offering of 17,272,728 shares of its common stock at a price to the public of $5.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 12,727,272 shares of common stock at a price to the public of $5.4999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants are to be sold by Sana. In addition, Sana has granted the underwriters a 30-day option to purchase up to an additional 4,500,000 shares of its common stock. The gross proceeds from the offering are expected to be approximately $165.0 million before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about February 12, 2024, subject to satisfaction of customary closing conditions.
02/07 16:01 EST - globenewswire.com
Sana Biotechnology Announces Proposed Public Offering of Common Stock
SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock. In addition, Sana intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock. All of the shares to be sold in this offering will be sold by Sana. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the proposed offering.
Sana Biotechnology Announces Proposed Public Offering of Common Stock
SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock. In addition, Sana intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock. All of the shares to be sold in this offering will be sold by Sana. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the proposed offering.
01/18 13:01 EST - zacks.com
Are You Looking for a Top Momentum Pick? Why Sana Biotechnology (SANA) is a Great Choice
Does Sana Biotechnology (SANA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are You Looking for a Top Momentum Pick? Why Sana Biotechnology (SANA) is a Great Choice
Does Sana Biotechnology (SANA) have what it takes to be a top stock pick for momentum investors? Let's find out.
01/18 11:27 EST - zacks.com
Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why
Sana Bio (SANA) rallies 105% after the company reports encouraging pipeline progress with its candidates, SC291 and SC262, for oncology and autoimmune indications.
Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why
Sana Bio (SANA) rallies 105% after the company reports encouraging pipeline progress with its candidates, SC291 and SC262, for oncology and autoimmune indications.
01/17 14:00 EST - seekingalpha.com
JD Henning Cautious About 2024, An Unusual Year For Market Considerations
JD Henning discusses his approach to the market and emphasizes the importance of timing and using momentum gauges to avoid major market downturns. Investing vs trading portfolios.
JD Henning Cautious About 2024, An Unusual Year For Market Considerations
JD Henning discusses his approach to the market and emphasizes the importance of timing and using momentum gauges to avoid major market downturns. Investing vs trading portfolios.
01/05 15:13 EST - seekingalpha.com
Sana Biotechnology: SC291 Moving Forward Beyond Hematological Malignancies
Additional results from a Sana Biotechnology, Inc. phase 1 study, using SC291 for the treatment of patients with B-cell lymphomas and leukemias, are expected in 2024. Initial results from phase 1 study, using SC291 for the treatment of patients with autoimmune disorders, expected in 2024. Initial results from phase 1 study, using SC262 for the treatment of patients with r/r B-cell Lymphomas who failed prior anti-CD19 therapies, expected in 2024.
Sana Biotechnology: SC291 Moving Forward Beyond Hematological Malignancies
Additional results from a Sana Biotechnology, Inc. phase 1 study, using SC291 for the treatment of patients with B-cell lymphomas and leukemias, are expected in 2024. Initial results from phase 1 study, using SC291 for the treatment of patients with autoimmune disorders, expected in 2024. Initial results from phase 1 study, using SC262 for the treatment of patients with r/r B-cell Lymphomas who failed prior anti-CD19 therapies, expected in 2024.
01/05 09:00 EST - globenewswire.com
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
SEATTLE, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application to initiate a study of SC262 in patients with relapsed or refractory B-cell malignancies, initially in patients who have received prior CD19-directed CAR T therapy. Engineered CAR T cell therapies for B-cell malignancies use binders to target proteins expressed on the surface of BÂ cells.
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
SEATTLE, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application to initiate a study of SC262 in patients with relapsed or refractory B-cell malignancies, initially in patients who have received prior CD19-directed CAR T therapy. Engineered CAR T cell therapies for B-cell malignancies use binders to target proteins expressed on the surface of BÂ cells.
01/03 16:05 EST - globenewswire.com
Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SEATTLE, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT on Tuesday, January 9, 2024. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SEATTLE, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT on Tuesday, January 9, 2024. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.